Ark 'extends runway until 2013' amid further restructuring
This article was originally published in Scrip
Executive Summary
Ark Therapeutics, the UK firm that suffered a catastrophic setback in December last year when the CHMP rejected its gene therapy candidate Cerepro (sitimagene ceradenovec) for the treatment of brain cancer in Europe, believes it has come up with a strategy that will extend its cash runway until 2013.